Evaluation of the outcomes in patients with chronic myeloid leukemia treated with imatinib in 18-year follow-up

• Main Authors: Mozafar Aznab, Ali Shahriari-Ahmadi, Fatemeh Heydarpour
• Format: Article
• Language: English
• Published: Elsevier 2021-01-01
• Series: Leukemia Research Reports
• Subjects: Molecular response rate; Chronic myeloid leukemia; Imatinib; Nilotinib
• Online Access: http://www.sciencedirect.com/science/article/pii/S2213048921000388

The objective of this paper is to examine the effects of Imatinib on patients who are at the chronic phase of chronic myeloid leukemia (CML). Method: Totally, 79 patients with CML who received the treatment between 2003 and 2020 entered the study. The patients were evaluated in terms of molecular response rate and overall survival (OS). Results: About 75.9% of patients achieved deep molecular response in mean follow-up of 89.92 months. The OS rate was about 91.2%. Conclusion: There was no considerable cumulative toxicity with Imatinib long-term use. A high percent of patients had a deep molecular response.